J Cancer 2020; 11(16):4841-4850. doi:10.7150/jca.46156 This issue

Research Paper

Application of cAMP-dependent catalytic subunit β (PRKACB) Low Expression in Predicting Worse Overall Survival: A Potential Therapeutic Target for Colorectal Carcinoma

Xiaoya Yao1,3*, Weixian Hu2,3*, Jie Zhang2,3*, Chengzhi Huang3,4*, Haibi Zhao1,3*, Xueqing Yao3,2,4,1,5✉

1. School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
2. The Second School of Clinical Medicine, Southern Medical University, Guangzhou, People's Republic of China.
3. Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China.
4. School of Medicine, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
5. Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
*These authors have contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Yao X, Hu W, Zhang J, Huang C, Zhao H, Yao X. Application of cAMP-dependent catalytic subunit β (PRKACB) Low Expression in Predicting Worse Overall Survival: A Potential Therapeutic Target for Colorectal Carcinoma. J Cancer 2020; 11(16):4841-4850. doi:10.7150/jca.46156. Available from https://www.jcancer.org/v11p4841.htm

File import instruction

Abstract

Low expressions of PRKACB are related to the occurrence of various human malignancies. However, the prognostic value of PRKACB expression in colorectal cancer (CRC) patients remains controversial. In this analysis, PRKACB expression in CRC tumors was evaluated across the GEO, TCGA, and Oncomine databases, and a PRKACB survival analysis was performed based on the TCGA profile. We detected PRKACB in 7 GEO series (GSE110225, GSE32323, GSE44076, GSE9348, GSE41328, GSE21510, GSE68468) and TCGA spectra (all P <0.05). A meta-analysis performed in the Oncomine database revealed that PRKACB was significantly up-regulated in neoplastic tissues compared to normal tissues (all P <0.05). A Kaplan-Meier analysis demonstrated that lower PRKACB expression in tumors was significantly associated with poorer overall survival (OS) in patients with CRC (P <0.05). A subgroup analysis showed that low expression of PRKACB correlated with poor 1-, 3-, and 5-year OS (all P <0.05). Furthermore, in males (P = 0.0083), whites (P = 0.0463), and non-mucinous adenocarcinoma patients (P = 0.0108), the down-regulation of PRKACB expression was more significant for the OS prognostic value. Conclusion: PRKACB is down-regulated in tumors and associated with worsening OS in CRC patients.

Keywords: PRKACB, colorectal carcinoma, survival, therapeutic target